Arbutus Q3 net loss $19.7M; imdusiran/AB-101 data upcoming; cash into Q4 2026

Arbutus Biopharma Corp

2024-Q3 EPS reported -$0.31 revenue$4,597,000

Net loss $19.7M ($0.10 per share) vs $20.1M prior year; revenue fell to $1.3M from $4.7M on lower license and royalty income.
Cash and investments $130.8M; 2024 cash burn expected $63M-$67M; runway into Q4 2026.
Imdusiran HBsAg loss data from IM-PROVE I/II to be presented at AASLD Nov 2024; additional follow-up and nivolumab cohort data.
AB-101 oral PD-L1 inhibitor advanced to Part 3 in cHBV patients; preliminary data expected H1 2025.
LNP litigation vs Moderna trial set Sept 2025; Pfizer claim construction Dec 18, 2024; restructuring charge $3.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.